Swept Source Optical Coherence Tomography Angiography for Cardiovascular Diseases

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Cardiovascular Diseases+1 More
Swept Source Optical Coherence Tomography Angiography - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether abnormalities in the retina's blood vessels, as seen on a special kind of OCT scan, are linked with the severity of cardiovascular disease as measured by ultrasound of the carotid arteries.

Eligible Conditions
  • Cardiovascular Diseases
  • retinal changes

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 2 hours

2 hours
Correlation with and prediction of the presence/degree of carotid occlusive disease as determined by carotid duplex ultrasonography

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

All Participants
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Swept Source Optical Coherence Tomography Angiography · No Placebo Group · N/A

All Participants
DiagnosticTest
Experimental Group · 1 Intervention: Swept Source Optical Coherence Tomography Angiography · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 hours

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,432 Previous Clinical Trials
769,487 Total Patients Enrolled
25 Trials studying Cardiovascular Diseases
39,945 Patients Enrolled for Cardiovascular Diseases
Rukhsana Mirza, MDPrincipal InvestigatorNorthwestern University

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are between the ages of 18 and 80 years.
You are able to consent.
Subjects receiving standard of care carotid duplex ultrasounds.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: October 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References